Matthew T Drake1, Joshua N Farr. 1. Division of Endocrinology, Metabolism, Nutrition and Diabetes, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Abstract
PURPOSE OF REVIEW: Recent data suggest that inhibitors of sclerostin, an osteocyte-produced Wnt signaling pathway antagonist, can stimulate bone formation. This review provides rationale and summarizes recent evidence supporting this novel approach to skeletal anabolism. RECENT FINDINGS: Data from numerous preclinical models in rodents and monkeys consistently demonstrate that antisclerostin monoclonal antibody (Scl-Ab) treatment leads to improvements in bone mass and strength, as well as enhanced fracture repair. Delivery of Scl-Ab therapy either subcutaneously or intravenously in phase 1 and 2 human clinical trials demonstrates short-term anabolic responses in excess of those seen with teriparatide, the only currently available anabolic skeletal agent. Gains have been primarily at central (spine and hips) versus peripheral (wrist) sites. Strikingly, Scl-Ab treatment appears to both stimulate bone formation and inhibit bone resorption in humans. If proven, Scl-Ab would be the first pharmacologic agent with such dual properties. Data on fractures are not yet available. SUMMARY: Scl-Ab therapy represents a novel pharmacologic approach to skeletal anabolism. Although many questions remain before Scl-Ab treatment can be introduced into clinical practice, phase 3 human clinical trials are currently underway and could provide the necessary data to bring this exciting class of skeletal anabolic agents to patient care.
PURPOSE OF REVIEW: Recent data suggest that inhibitors of sclerostin, an osteocyte-produced Wnt signaling pathway antagonist, can stimulate bone formation. This review provides rationale and summarizes recent evidence supporting this novel approach to skeletal anabolism. RECENT FINDINGS: Data from numerous preclinical models in rodents and monkeys consistently demonstrate that antisclerostin monoclonal antibody (Scl-Ab) treatment leads to improvements in bone mass and strength, as well as enhanced fracture repair. Delivery of Scl-Ab therapy either subcutaneously or intravenously in phase 1 and 2 human clinical trials demonstrates short-term anabolic responses in excess of those seen with teriparatide, the only currently available anabolic skeletal agent. Gains have been primarily at central (spine and hips) versus peripheral (wrist) sites. Strikingly, Scl-Ab treatment appears to both stimulate bone formation and inhibit bone resorption in humans. If proven, Scl-Ab would be the first pharmacologic agent with such dual properties. Data on fractures are not yet available. SUMMARY:Scl-Ab therapy represents a novel pharmacologic approach to skeletal anabolism. Although many questions remain before Scl-Ab treatment can be introduced into clinical practice, phase 3 human clinical trials are currently underway and could provide the necessary data to bring this exciting class of skeletal anabolic agents to patient care.
Authors: Xiaodong Li; Kelly S Warmington; Qing-Tian Niu; Franklin J Asuncion; Mauricio Barrero; Mario Grisanti; Denise Dwyer; Brian Stouch; Theingi M Thway; Marina Stolina; Michael S Ominsky; Paul J Kostenuik; William S Simonet; Chris Paszty; Hua Zhu Ke Journal: J Bone Miner Res Date: 2010-07-16 Impact factor: 6.741
Authors: Michael S Ominsky; Fay Vlasseros; Jacquelin Jolette; Susan Y Smith; Brian Stouch; George Doellgast; Jianhua Gong; Yongming Gao; Jin Cao; Kevin Graham; Barbara Tipton; Jill Cai; Rohini Deshpande; Lei Zhou; Michael D Hale; Daniel J Lightwood; Alistair J Henry; Andrew G Popplewell; Adrian R Moore; Martyn K Robinson; David L Lacey; W Scott Simonet; Chris Paszty Journal: J Bone Miner Res Date: 2010-05 Impact factor: 6.741
Authors: Michael S Ominsky; Chaoyang Li; Xiaodong Li; Hong L Tan; Edward Lee; Mauricio Barrero; Franklin J Asuncion; Denise Dwyer; Chun-Ya Han; Fay Vlasseros; Rana Samadfam; Jacquelin Jolette; Susan Y Smith; Marina Stolina; David L Lacey; William S Simonet; Chris Paszty; Gang Li; Hua Z Ke Journal: J Bone Miner Res Date: 2011-05 Impact factor: 6.741
Authors: Christine Hamann; Martina Rauner; Yvonne Höhna; Ricardo Bernhardt; Jan Mettelsiefen; Claudia Goettsch; Klaus-Peter Günther; Marina Stolina; Chun-Ya Han; Franklin J Asuncion; Michael S Ominsky; Lorenz C Hofbauer Journal: J Bone Miner Res Date: 2013-03 Impact factor: 6.741
Authors: Jordan M Spatz; Rachel Ellman; Alison M Cloutier; Leeann Louis; Miranda van Vliet; Larry J Suva; Denise Dwyer; Marina Stolina; Hua Zhu Ke; Mary L Bouxsein Journal: J Bone Miner Res Date: 2013-04 Impact factor: 6.741
Authors: Ryan D Ross; Lindsey H Edwards; Alvin S Acerbo; Michael S Ominsky; Amarjit S Virdi; Kotaro Sena; Lisa M Miller; D Rick Sumner Journal: J Bone Miner Res Date: 2014-07 Impact factor: 6.741
Authors: Alison Eddleston; Massimo Marenzana; Adrian R Moore; Paul Stephens; Mariusz Muzylak; Diane Marshall; Martyn K Robinson Journal: J Bone Miner Res Date: 2009-10 Impact factor: 6.741
Authors: Azusa Maeda; Mitsuaki Ono; Kenn Holmbeck; Li Li; Tina M Kilts; Vardit Kram; Megan L Noonan; Yuya Yoshioka; Erin M B McNerny; Margaret A Tantillo; David H Kohn; Karen M Lyons; Pamela G Robey; Marian F Young Journal: J Biol Chem Date: 2015-04-11 Impact factor: 5.157
Authors: Mohammad M Alzahrani; Asim M Makhdom; Frank Rauch; Dominique Lauzier; Maria Kotsiopriftis; Saber Ghadakzadeh; Reggie C Hamdy Journal: J Bone Miner Metab Date: 2017-06-24 Impact factor: 2.626